Vichem is a Hungarian biotech research company and performs advanced medicinal chemistry in the kinase inhibitory field based on its unique, in-house developed, Nested Chemical Library™ (NCL) technology. With over 20 years of experience in kinase inhibitory chemistry we have established an outstanding knowledge base that has helped to develop the NCL. Our library is organized around more than 110 core structures and more than 600 scaffolds, and contains inhibitors against more than 160 kinases, providing the most diverse kinase inhibitory library available for drug research. In around a year we can deliver a novel patentable, submicromolar lead compound against a selected kinase with about 4-5 research cycles using our innovative NCL, Masterkey, Pharmacophore and Scaffold Hopping technologies. Our Tool Compound Library(TCL) technology enables us to perform selectivity profiling and off-target identification. TCL compounds can be labelled with fluorescent dyes a used as tracers. Vichem is highly skilled in developing preclinical candidates with lead optimization for efficacy and ADMET properties. Vichem has nM lead compounds against 20 kinase targets in cancer, inflammatory and infectious diseases. Vichem has developed lead compounds against various kinase targets for its collaborative partners. Vichem has lead compounds and/or early preclinical candidates for TB, Influenza, AIDS and 5 pathological kinase targets. Vichem established partnership with various European, American and Japanese institutions and companies, participates in several FP7 projects.